Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
AGTC-501 Offers Vision Gains for X-Linked RP
Inherited retinal diseases (IRDs), also referred to as inherited retinal dystrophies, are a clinically and genetically heterogeneous group of neurodegenerative disorders, primarily involving photoreceptors, retinal pigment epithelium (RPE), and/or the choroid. Taken as a whole, IRDs have an estimated global…
FDA Approves Cyclosporine Eye Drops
Verkazia 0.1%) eye drops containing cyclosporine have been authorized by the US Food and Drug Administration (FDA) for the treatment of vernal keratoconjunctivitis (VKC) in both adult and juvenile populations. The surface of the eyes in patients with the uncommon,…
Improved Vision Through A Supplement
Mexican marigold also known as cempasúchil, or Aztec marigold is a native flower to México and was first used by the Aztecs and is used in the Mexican holiday “Dia de los muertos” or day of the dead. The Aztecs used it…
TelomEYE Pharma Raises $1M in Post-Seed Funding
TelomEYE Pharmaceuticals Corporation, working on a new generation of ophthalmologic therapies, announced today the completion of a successful $1 million post-seed funding round, valuing the company at $10 million USD. The round was co-led by healthcare mogul Mehmet Ali Aydınlar,…
Oral Azithromycin vs Doxycycline for MGD
A study published online in JAMA Ophthalmology found that treatment of severe meibomian gland dysfunction (MGD) with three weeks of oral azithromycin is equivalent to six weeks of doxycycline. The study was conducted by Phit Upaphong, M.D., from Chiang Mai…
Jeff Farrow Becomes New CFO and CSO at Tarsus
Tarsus Pharmaceuticals has appointed Jeff Farrow as both Chief Financial Officer and Chief Strategy Officer, effective immediately. Farrow replaces Leo Greenstein, who had been CFO since 2020 but is leaving the company to pursue other professional interests. Farrow has over…
Haag-Streit Launches New EyeSuite Software
Haag-Streit has recently launched EyeSuite software version i9.13, which comes with new features for the Anterior Chamber Suite of the Eyestar 900, as well as market-first functionality for the Lenstar Myopia. Furthermore, Haag-Streit has made additional improvements to its existing…
Ocumension Submits NDA for Zerviate in China
Nicox SA announced that its exclusive Chinese partner, Ocumension Therapeutics, has submitted a new drug application (NDA) seeking approval for commercialization of Zerviate (cetirizine ophthalmic solution), 0.24%, in China. The intended use of Zerviate is for the treatment of ocular…
Tepezza Improves Proptosis in Patients With Chronic TED
Horizon Therapeutics has announced positive and statistically significant topline results from its randomized, double-masked, placebo-controlled Phase 4 clinical trial evaluating TEPEZZA for the treatment of adults with chronic thyroid eye disease (TED) and low CAS, a measure of disease activity.…
Ultomiris Poised for EU Approval as NMOSD Treatment
AstraZeneca’s Ultomiris (ravulizumab) has received a recommendation for marketing authorization in the European Union (EU) for the treatment of adult patients who are anti-aquaporin-4 (AQP4) antibody positive (Ab+) and have neuromyelitis optica spectrum disorder (NMOSD). If authorized, Ultomiris would become…